Company: LENZ
Filing Date: 2025-04-14
Form Type: 424B5
Source: 0001628280-25-017695
Chunk: 9

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-14
Form: 424B5
Chunk 9
---
. 2020 Equity Incentive Plan (the “2020 Plan”), which were assumed by the Company in connection with the Merger, with a weighted average exercise price of $4.28 per share; • 8,438 shares of our common stock issuable upon the exercise of outstanding options under the LENZ Therapeutics, Inc. (f/k/a Graphite Bio, Inc.) 2021 Stock Option and Incentive Plan (the “2021 Plan”), with a weighted average exercise price of $11.94 per share; • 1,522,550 shares of our common stock issuable upon the exercise of outstanding options under the LENZ Therapeutics, Inc. 2024 Equity Incentive Plan (the “2024 Plan”), with a weighted average exercise price of $16.45 per share; • 790,139 shares of common stock issuable upon the exercise of stock options granted pursuant to the 2024 Plan subsequent to December 31, 2024, with a weighted average exercise price of $26.00 per share; • 30,500 shares of common stock issuable upon the vesting of restricted stock units granted pursuant to the 2024 Plan subsequent to December 31, 2024;

<div align='center'>S-5</div>

• 1,544,122 shares of our common stock reserved for future issuance under our 2024 Plan, as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan; and

• 250,995 shares of our common stock reserved for future issuance under our 2024 Employee Stock Purchase Plan (the “2024 ESPP”), as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan.

Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of outstanding options after December 31, 2024.

The share numbers set forth above also exclude the automatic increases in the shares reserved under the 2024 Plan and the 2024 ESPP that were effective January 1, 2025.

<div align='center'>S-6</div>

### RISK FACTORS
Investing in our common stock involves risk. You should carefully consider the specific risks discussed below, together with all the other information contained in the prospectus supplement, accompanying prospectus or incorporated by reference into this prospectus supplement. You should also consider the risks, uncertainties and assumptions discussed under the caption “Risk Factors” included